Literature DB >> 9200779

Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity.

I Nowak1, L M Shaw.   

Abstract

Mycophenolic acid glucuronide (MPAG) inhibition kinetics were evaluated using purified recombinant human type II inosine monophosphate dehydrogenase (IMPDH). MPAG inhibitory concentrations (IC50) were found to be 532- to 1022-fold higher than those for MPA. As expected, according to tight-binding inhibitor kinetics, mycophenolic acid (MPA) IC50 values increased as IMPDH concentrations increased, whereas IC50 values for xanthosine monophosphate (competitive IMPDH inhibitor used as control), an inhibitor known not to be tight binding, remained independent of enzyme concentration. Although MPAG exhibited only weak inhibition of IMPDH activity, in comparison with MPA, IC50 values increased with increasing enzyme concentration. The presence of trace quantities of MPA (0.2% on a molar basis) in the MPAG preparation, detected by high-performance liquid chromatography analysis, could account for this observation. These data support the proposal that MPAG is a pharmacologically inactive metabolite of MPA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200779     DOI: 10.1097/00007691-199706000-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.

Authors:  Olivier Gensburger; Ron H N Van Schaik; Nicolas Picard; Yannick Le Meur; Annick Rousseau; Jean-Baptiste Woillard; Teun Van Gelder; Pierre Marquet
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

3.  Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.

Authors:  M Shipkova; V W Armstrong; E Wieland; P D Niedmann; E Schütz; G Brenner-Weiss; M Voihsel; F Braun; M Oellerich
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.

Authors:  Malek Okour; Pamala A Jacobson; Mariam A Ahmed; Ajay K Israni; Richard C Brundage
Journal:  J Clin Pharmacol       Date:  2018-01-12       Impact factor: 3.126

5.  Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes.

Authors:  M Shipkova; C P Strassburg; F Braun; F Streit; H J Gröne; V W Armstrong; R H Tukey; M Oellerich; E Wieland
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

6.  Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation.

Authors:  Lihua Zeng; Elaine Y L Blair; Christa E Nath; Peter J Shaw; John W Earl; Katherine Stephen; Kay Montgomery; John C Coakley; Elisabeth Hodson; Michael Stormon; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

7.  Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.

Authors:  B Shum; S B Duffull; P J Taylor; S E Tett
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

8.  Development of a Formula to Correct Particle-Enhanced Turbidimetric Inhibition Immunoassay Values so That it More Precisely Reflects High-Performance Liquid Chromatography Values for Mycophenolic Acid.

Authors:  Keiichi Nakano; Daiki Iwami; Takehiro Yamada; Ken Morita; Keiko Yasuda; Hitoshi Shibuya; Kaoru Kahata; Nobuo Shinohara; Chikara Shimizu
Journal:  Transplant Direct       Date:  2017-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.